Upon request of a Health Care Professional (HCP) and with the approval from ANSM, lntsel Chimos provides compassionate access to drugs that do not have a marketing authorization (MA) in France to allow HCP to treat rare or serious pathologies that have reached a therapeutic impasse.
INTSEL CHIMOS GUARANTEES...
CLINICAL STUDIES DISTRIBUTION
As part of its commitment to early access to innovation, lntsel Chimos is authorized to distribute products intended for human experimentation. This delicate operation requires specific expertise and is deeply embedded in all stages of our supply chain.
CONDITIONS & TRACEABILITY
Intsel Chimos team takes every precaution to
handle and manage these sensitive products
within their own strict regulatory framework.
We are committed to supporting clinical studies sponsors throughout the duration of their trials, in particular by guaranteeing the quality of the handling, storage, safety and traceability of their products.
EXPERIENCE & INVOLVEMENT
Based on our involvement in treating patients, our knowledge of AAC, and our experience on the French market, we are the partner of choice for pharmaceutical companies in their market access process, depending on the development phase of their pharmaceutical products.
PHASES OF A CLINICAL STUDIES
You wish to be accompanied in clinical studies or to import/export a treatment to France or Europe ?
Depuis le 4 septembre 2023, nous sommes l’exploitant et le distributeur de RUBRACA® (disponible sous 3 présentations RUBRACA® 200mg / RUBRACA® 250mg & RUBRACA® 300mg) indiqué en oncologie. Vous devez envoyer vos commandes par email à l’adresse : firstname.lastname@example.org